Addex Therapeutics (ADXN) Non Operating Income (2018 - 2025)

Addex Therapeutics has disclosed Non Operating Income across 8 years of filings, most recently posting -$1765.4 for Q4 2025.

• Non Operating Income for Q4 2025 came in at -$1765.4, down 105.67% year-over-year; the trailing twelve-month figure through Dec 2025 was -$17043.1 (down 162.9% YoY), and the FY2025 annual result was -$18751.7, down 171.27% from the prior year.
• Non Operating Income came in at -$1765.4 for Q4 2025 at Addex Therapeutics, down from -$1021.3 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $562337.0 in Q1 2021 to a low of -$294798.2 in Q4 2022.
• The 5-year median for Non Operating Income is -$22827.4 (2021), against an average of -$31789.7.
• Peak annual rise in Non Operating Income reached 2482.99% in 2024, while the deepest fall reached 180.6% in 2024.
• Addex Therapeutics' Non Operating Income stood at -$161089.8 in 2021, then sank by 83.0% to -$294798.2 in 2022, then rose by 1.72% to -$289730.1 in 2023, then jumped by 110.74% to $31129.3 in 2024, then sank by 105.67% to -$1765.4 in 2025.
• The last three Non Operating Income figures came in at -$1765.4 (Q4 2025), -$1021.3 (Q3 2025), and $7043.2 (Q2 2025), per Business Quant data.